Proactive Investors - Run By Investors For Investors

Synairgen making headway

The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints
lung in x-ray
It is is currently running a two-part phase II trial evaluating SNG001
  • Focused on respiratory disease

  • Two drugs candidates, one being developed in-house the other by a partner

  • Financially well set to progress its key asset, analyst says

 

Respiratory specialist

Synairgen plc (LON:SNG) is currently running a two-part phase II trial evaluating SNG001. This is an inhaled interferon beta drug candidate designed for people with chronic obstructive pulmonary disease (COPD) who are also suffering cold or flu infections.

It has completed the first part of its SG015 study, assessing the safety of the treatment. The second instalment is underway at 13 separate sites.

In an update, the company said the milder start to the current virus season means Synairgen expects the trial to continue into the 2019/20 peak period for cold and flu.

LOXL2

The company’s Australian partner has completed phase I trials and toxicology on a LOXL2 inhibitor developed by Synairgen.

This now paves the way for Pharmaxis to advance discussions with potential partners for the drug, which has been developed to treat non-alcoholic liver disease (NASH) and a rare lung condition.

The company retains a 17% “carried interest” in the asset.

Synairgen’s BioBank

Over the years, Synairgen has accumulated an extensive bank comprised of blood, sputum, nasal lavage, biopsies, bronchial epithelial cells and fibroblasts from volunteers with asthma or COPD. Using this resource, the company has developed a number of advanced tissue models.

It uses these models to:

•        Discover novel drug targets

•        Identify disease-related lesions and underlying molecular mechanisms

•        Conduct proof of concept testing and validation of novel drug targets

•        Conduct screening assays for novel drug targets and lead target selection

•        Provide support for clinical trial activities

Financially solid

The company ended last year with £5.33mln in the bank, having raised £2.7mln.

Research and development costs were £3.23mln, while the company posted a loss of £4.13mln for the 12 months to December 31.

What the broker says

Mark Brewer of small-cap specialist finnCap said the adjusted net loss was £1.3mln better than he had been forecasting. He added that year-end cash of £5.3mln was “sufficient to more than cover the cost of the ongoing phase IIa study of SNG001”.

On the slower than expected sign-up rate for the trial, he added: “We are hugely reassured by the fact that all patients enrolled are virus-positive, which increases the probability of SNG001 showing a drug-related effect.”

Brewer’s price target for the stock is 54p. The shares are currently changing hands for 15p.

View full SNG profile View Profile

Synairgen plc Timeline

Big Picture
May 07 2019
Article
February 25 2019

Related Articles

test tubes
May 02 2019
Proactive takes a closer look at an innovative drugs company that has largely flown under the radar
1550850611_CancerHeadline.jpg
February 22 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”
copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use